



Cite this: *Dalton Trans.*, 2016, **45**, 13034

Received 9th April 2016,
Accepted 6th May 2016

DOI: 10.1039/c6dt01382a

www.rsc.org/dalton

Spin-labelled photo-cytotoxic diazido platinum(IV) anticancer complex†

V. Venkatesh,^a Christopher J. Wedge,^b Isolda Romero-Canelón,^a
Abraha Habtemariam^a and Peter J. Sadler^{*a}

We report the synthesis and characterisation of the nitroxide spin-labelled photoactivatable Pt(IV) prodrug *trans,trans,trans*-[Pt(N₃)₂(OH)(OCOCH₂CH₂CONH-TEMPO)(Py)₂] (Pt-TEMPO, where TEMPO = 2,2,6,6-tetramethylpiperidine 1-oxyl). Irradiation with blue visible light gave rise to Pt(II) and azidyl as well as nitroxyl radicals. Pt-TEMPO exhibited low toxicity in the dark, but on photoactivation was as active towards human ovarian cancer cells as the clinical photosensitizer chlorpromazine and much more active than the anticancer drug cisplatin under the conditions used.

Platinum-based anticancer drugs are now widely used for the treatment of various types of cancer.^{1–3} However, their utility in the clinic is severely limited by their systemic toxicity, as well as inherent and acquired drug resistance.^{4–6} Photo-activated chemotherapy (PACT) has recently attracted attention because of its ability to target tumour cells selectively without causing harm to normal cells thereby minimising side effects.⁷ The advantages of using metal complexes in PACT stem from their rich photochemistry.^{8,9} This can be utilized in the design of a non-toxic prodrug that can be selectively activated in the region of a tumour using light of specific wavelengths, with longer wavelengths penetrating more deeply into tissues.

Nitroxide spin-labelling can provide a convenient way of monitoring drug distribution and metabolic pathways using electron paramagnetic resonance (EPR).^{10–12} Nitroxyl radicals often exhibit low toxicity, are membrane-permeable and also possess antioxidant activity that mimics superoxide dismutase (SOD).¹³ The potent anticancer activity of nitroxide radicals, nitroxyl derivatives and their metal complexes towards a variety of cancer cell lines has been reported,^{14–17} and often

involves redox-mediated signalling pathways.¹⁸ Nitroxide radicals not only have diagnostic use, but also therapeutic, and hence are potential ‘theranostics’ as well. We report here what appears to be (as far as we are aware) the first example of the photo-release of a nitroxide radical from a metal complex and its antiproliferative activity towards cancer cells.

We have synthesised the TEMPO-conjugated photo-activatable Pt(IV) prodrug *trans,trans,trans*-[Pt(N₃)₂(OH)(OCOCH₂CH₂CONH-TEMPO)(Py)₂] (Pt-TEMPO, Fig. 1a) and studied its photocytotoxicity towards A2780 human ovarian cancer cells. The synthesis was achieved by reacting *trans,trans,trans*-[Pt(N₃)₂(OH)(succinate)(Py)₂] with 4-amino TEMPO using a 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) coupling reaction (ESI, Scheme S1†). The product was purified by column chromatography and characterized by ¹H NMR, elemental analysis and high resolution mass spectrometry (HRMS). The presence of the TEMPO radical in the complex was confirmed by EPR spectroscopy. The EPR spectrum of Pt-TEMPO (0.5 mM in dichloromethane) recorded at room temperature showed a typical triplet pattern with distinct ¹⁴N hyperfine splitting (Fig. 1c).

The ¹H NMR spectrum of Pt-TEMPO in CDCl₃ shows broadened peaks (Fig. S1 ESI†) indicating the presence of the TEMPO




Fig. 1 (a) Molecular structure of Pt-TEMPO complex; (b) calculated and observed HR-ESI-MS spectra of Pt-TEMPO with isotopic distribution; (c) EPR spectrum of Pt-TEMPO (0.5 mM) in degassed dichloromethane.

^aDepartment of Chemistry, University of Warwick, Coventry CV4 7AL, UK.

E-mail: P.J.Sadler@warwick.ac.uk

^bDepartment of Physics, University of Warwick, Coventry CV4 7AL, UK.

E-mail: c.wedge@warwick.ac.uk

†Electronic supplementary information (ESI) available. See DOI: 10.1039/c6dt01382a. Data created during this research are openly available from the University of Warwick Research Archive Portal at <http://wrap.warwick.ac.uk/79055/>

radical attached to the diazido Pt(IV) complex. The peaks in the aromatic region of the spectrum indicate the presence of pyridine ligands and the signals at (2.3–2.8 ppm) correspond to the methylene protons in the succinate chain. The signals at (0.9–1.3 ppm) confirmed the successful conjugation of TEMPO unit in Pt-TEMPO. The observed HRMS is in good agreement with the spectrum calculated for $[M + Na]^+$, Fig. 1b.

Pt-TEMPO was irradiated with 420 nm light in aqueous solution. The progress of the photoreaction was monitored at different time intervals by UV-Vis spectroscopy and the decomposition products were subsequently analysed by ESI-MS. The change in ligand-to-metal charge-transfer (LMCT) band for Pt-TEMPO was monitored after every 30 min of photoactivation at 420 nm up to 2 h Fig. 2c. The reduction in LMCT band indicates that there is loss of an azido ligand and/or electron transfer from azido ligands to Pt(IV) resulting in the for-

mation of azidyl radicals and Pt(IV/II) species. ESI-MS shows the formation of a mixture of products 1–4 in solution after photoactivation Fig. 2a (ESI, Fig. S3†). When the photoactivation was carried out using green light (517 nm), the reduction in intensity of the LMCT band was very slow (ESI, Fig. S5†) due to the weaker absorbance of Pt-TEMPO at 517 nm.

To capture the reactive azidyl radicals, spin-trapping experiments were performed. An aqueous solution containing 1 mM of Pt-TEMPO and 25 mM 5,5-dimethyl-1-pyrroline-*N*-oxide (DMPO), giving a 12.5 fold molar excess of spin-trap over azide, was used for the experiment. The EPR spectrum was recorded in the dark and during irradiation with a 405 nm laser (42 mW). In the absence of irradiation the EPR spectrum showed a triplet signal characteristic of the 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO) radical present in Pt-TEMPO (Fig. S4†). Upon irradiation with the blue laser the azidyl




Fig. 2 (a) Photoreaction pathways for Pt-TEMPO (0.1 mM in H₂O) on irradiation with blue visible light showing formation of products 1–4; (b) EPR spectrum of Pt-TEMPO with DMPO in the dark as well as after irradiation with $\lambda_{\text{irr}} = 405$ nm laser (each consecutive scan took 21 s to record); (c) UV-Vis spectrum of Pt-TEMPO after every 30 min of irradiation ($\lambda_{\text{irr}} = 420$ nm).



adduct of DMPO was detected. This gave a 1 : 2 : 2 : 1 quartet of triplets signal along with the triplet signal of the stable TEMPO radical. During irradiation, spectra were recorded continuously with each successive field-sweep taking 21 s (Fig. 2b).

Due to the overlap of peaks for Pt-TEMPO and the DMPO- N_3 adduct, and the significant intensity difference between them, it is difficult to obtain accurate spin Hamiltonian parameters of the weaker component through a multi-component fit. For simulations of the DMPO azidyl adduct the hyperfine couplings were therefore fixed to literature values ($a_{NO}^N = 1.45$ mT, $a_{\beta}^H = 1.49$ mT, $a_{\alpha}^N = 0.316$ mT).¹⁹ By subtracting the experimental data recorded before illumination from those recorded after illumination, the Pt-TEMPO signal intensity was significantly reduced allowing the twelve-line azidyl spin-adduct signal to be observed clearly (Fig. 3a). As $a_{NO}^N \approx a_{\beta}^H$ the usual DMPO doublet of triplets overlaps to form a 1 : 2 : 2 : 1 quartet, with each line further split into a triplet by the small coupling to the azidyl nitrogen. This spectral assignment has been confirmed previously in photoactivation studies of a closely related Pt-azidyl anti-cancer compound by use of ^{15}N labelled azide,¹⁹ hence it was not considered necessary to perform isotopic substitution experiments.

Once individual spectral simulations for Pt-TEMPO and the azidyl radical adduct had been completed using EasySpin²⁰ it was possible to reproduce the overlapping experimental

spectra as linear combinations of the two (Fig. 3b). The scaling parameter between simulated and experimental spectra was determined from a least-squares fit of the simulated Pt-TEMPO spectra to the experimental spectra prior to illumination. Treating this value as a constant and using the known initial Pt-TEMPO concentration of 1 mM as a reference, it was possible to determine the azidyl adduct concentration from the weighting factor of the combined fit. Running the spectrometer in incremental scan mode, a series of field-swept spectra was recorded consecutively, which by individual fitting with the simulated spectra allowed measurement of the azidyl-adduct concentration as a function of time since illumination began (Fig. 3c).

The photocytotoxicity of Pt-TEMPO was determined by using the sulforhodamine B (SRB) colorimetric assay which quantifies protein content of treated samples against untreated controls. A2780 human ovarian carcinoma cells were treated with Pt-TEMPO for 1 h in the dark and also treated with Pt-TEMPO followed by irradiation with blue light (50 mW at 465 nm) for 1 h. The complex was not toxic in the dark but potentially cytotoxic when irradiated in the cells with blue visible light, giving a phototoxicity index (PI) of >8. A2780 cells are >14× more sensitive to Pt-TEMPO than to cisplatin when treated under the same conditions. The activity of cisplatin was not affected by the irradiation. The photocytotoxicity of Pt-TEMPO is similar to that²¹ of the parent *trans*-dihydroxido




Fig. 3 (a) Overlap of experimental and simulated DMPO- N_3 adduct spectra. The experimental trace shows the subtraction of spectra recorded immediately before and after switch on of the light source. Stars indicate the location of the three main lines in the TEMPO spectrum which are not fully subtracted; (b) comparison between simulated and experimental EPR spectra of Pt-TEMPO and DMPO- N_3 ; (c) azide spin-adduct concentration as a function of illumination time (42 mW at 405 nm) determined by least-squares fitting of the sum of simulated Pt-TEMPO and DMPO- N_3 spectra to the experimental EPR traces.



Table 1 Photocytotoxicity of Pt-TEMPO against A2780 human ovarian carcinoma cells in comparison with $[\text{Pt}(\text{N}_3)_2(\text{OH})_2(\text{Py})_2]$, chlorpromazine (CPZ) and cisplatin (CDDP). Experiments included 1 h of drug exposure time and 1 h of irradiation (50 mW at 465 nm), followed by 24 h of recovery time in drug-free medium. Results are expressed as the average of triplicates and its standard deviation

Compound	$\text{IC}_{50}(\mu\text{M})$	
	+465 nm	Dark
Pt-TEMPO	5.9 ± 0.2	>50
$[\text{Pt}(\text{N}_3)_2(\text{OH})_2(\text{Py})_2]$	7.1 ± 0.4	>60
CPZ	6.2 ± 0.3	>100
CDDP	>80	>80

complex $[\text{Pt}(\text{N}_3)_2(\text{OH})_2(\text{Py})_2]$ which shows that replacement of one axial hydroxide ligand by a TEMPO-conjugated succinate ligand does not diminish the activity. Interestingly, the activity of the new complex Pt-TEMPO is as high as the organic photosensitizer chlorpromazine (CPZ) (Table 1).

In summary, a diazido Pt(IV) pro-drug *trans,trans,trans*- $[\text{Pt}(\text{N}_3)_2(\text{OH})(\text{OCOCH}_2\text{CH}_2\text{CONH-TEMPO})(\text{Py})_2]$ (Pt-TEMPO) spin-labelled with a nitroxyl radical has been synthesised. It is non-toxic in the dark but potentially cytotoxic towards cancer cells when irradiated with visible light. The photocytotoxicity is as high as the clinical photosensitizer chlorpromazine and much more cytotoxic than anticancer drug cisplatin under the same conditions. EPR experiments showed that photoactivation of Pt-TEMPO with blue light leads to the formation of azidyl and TEMPO radicals in solution. The reactive azidyl radicals were captured by the spin trap DMPO. The anticancer activity of Pt-TEMPO may be the result of attack on DNA by the Pt(II) photoproducts as well as the activity of the reactive azidyl and appended TEMPO radicals. The complex should be suitable for the treatment of surface cancers such as bladder and oesophagus, and if deeper light penetration is required then either two-photon activation or coupling to an upconversion nanoparticle system may be possible.^{22,23}

Acknowledgements

We thank the Newton International Fellowship program (VV), EPSRC (grant no EP/J500045/1, CJW), and ERC (grant no. 247450, IRC, PJS) for support, and Mr James Coverdale for his excellent assistance with ICP experiments.

Notes and references

- 1 F. M. Muggia, A. Bonetti, J. D. Hoeschele, M. Rozenzweig and S. B. Howell, *J. Clin. Oncol.*, 2015, **33**, 4219.
- 2 T. C. Johnstone, K. Suntharalingam and S. J. Lippard, *Chem. Rev.*, 2016, **116**, 3436.
- 3 M. S. Robillard and J. Reedijk, *Encyclopedia of Inorganic and Bioinorganic Chemistry*, 2011, DOI: 10.1002/9781119951438.eibc0178.
- 4 J. T. Hartmann and H. P. Lipp, *Expert Opin. Pharmacother.*, 2003, **4**, 889.
- 5 J. T. Hartmann, C. Kollmannsberger, L. Kanz and C. Bokemeyer, *Int. J. Cancer*, 1999, **83**, 866.
- 6 A. Florea and D. Büsselberg, *Cancer*, 2011, **3**, 1351.
- 7 N. J. Farrer, L. Salassa and P. J. Sadler, *Dalton Trans.*, 2009, 10690.
- 8 C. Daniel, *Coord. Chem. Rev.*, 2015, **282–283**, 19.
- 9 N. A. Smith and P. J. Sadler, *Philos. Trans. R. Soc. London, Ser. A*, 2013, **371**, 1.
- 10 S. Hirose, S. Araib and S. Takeoka, *Chem. Commun.*, 2012, **48**, 4845.
- 11 D. Tatlidil, M. Ucuncu and Y. Akdogan, *Phys. Chem. Chem. Phys.*, 2015, **17**, 22678.
- 12 G. Martini and L. Ciani, *Phys. Chem. Chem. Phys.*, 2009, **11**, 211.
- 13 T. Offer, A. Russo and A. Samuni, *FASEB J.*, 2000, **14**, 1215.
- 14 S. Suy, J. B. Mitchell, D. Ehleiter, A. H. Friedman and U. Kasid, *J. Biol. Chem.*, 1998, **273**, 17871.
- 15 V. D. Sen', *Russ. Chem. Bull.*, 1993, **42**, 507.
- 16 V. D. Sen', V. A. Golubev, L. M. Volkova and N. P. Konovalova, *J. Inorg. Biochem.*, 1996, **64**, 69.
- 17 V. B. Arion, A. Dobrov, S. Goschl, M. A. Jakupc, B. K. Keppler and P. Rapta, *Chem. Commun.*, 2012, **48**, 8559.
- 18 G. T. Wondrak, *Antioxid. Redox Signaling*, 2009, **11**, 3013.
- 19 J. S. Butler, J. A. Woods, N. J. Farrer, M. E. Newton and P. J. Sadler, *J. Am. Chem. Soc.*, 2012, **134**, 16508.
- 20 S. Stoll and A. Schweiger, *J. Magn. Reson.*, 2006, **178**, 42.
- 21 N. J. Farrer, J. A. Woods, L. Salassa, Y. Zhao, K. S. Robinson, G. Clarkson, F. S. Mackay and P. J. Sadler, *Angew. Chem., Int. Ed.*, 2010, **49**, 8905.
- 22 Y. Zhao, G. M. Roberts, S. E. Greenough, N. J. Farrer, M. J. Paterson, W. H. Powell, V. G. Stavros and P. J. Sadler, *Angew. Chem., Int. Ed.*, 2012, **51**, 11263.
- 23 Y. Min, J. Li, F. Liu, E. K. L. Yeow and B. Xing, *Angew. Chem., Int. Ed.*, 2014, **53**, 1012.

